Biomarkers in chronic obstructive pulmonary disease

Translational Research

Volumn 159, Issue 4, 2012, Pages 228-237

  Rosenberg, Sharon R ^a   Kalhan, Ravi ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLARA CELL PROTEIN; CORTICOSTEROID; DESMOSINE; ERYTHROMYCIN; FIBRINOGEN; FLUTICASONE; INTERLEUKIN 6; PLACEBO; ROFLUMILAST; SALMETEROL; SERUM AMYLOID A; SURFACTANT PROTEIN D; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ACUTE DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG APPROVAL; DYSPNEA; EMPHYSEMA; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; INFLAMMATION; LOW DRUG DOSE; LUNG FUNCTION; LUNG RESECTION; META ANALYSIS (TOPIC); NEUTROPHIL COUNT; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SMALL AIRWAY DISEASE; SPUTUM; SPUTUM ANALYSIS; TREATMENT RESPONSE;

EID: 84858385254     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.01.019     Document Type: Review

References (104)

1. Kochanek K, Xu J, S. M, Minino A, H. K. Deaths: preliminary data for 2009. National Center for Health Statistics, Hyattsville, MD, 2011.
2. NHLBI Morbidity and Mortality Chartbook. Available at: http://www.nhlbi.nih.gov/resources/docs/cht-bookhtm Accessed August 26, 2011.
3. C.D. Mathers, and D. Loncar Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med 3 2006 e442
4. B.R. Celli, W. MacNee, and A. Agusti Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper Eur Respir J 23 2004 932 946
5. K.F. Rabe, S. Hurd, and A. Anzueto Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 176 2007 532 555
6. R. Antonelli-Incalzi, C. Imperiale, and V. Bellia Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J 22 2003 444 449
7. C.B. Cooper The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function Am J Med 119 2006 21 31
8. A.J. Atkinson Jr, W.A. Colburn, and G. Victor Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
9. J. Vestbo, and S. Rennard Chronic obstructive pulmonary disease biomarker(s) for disease activity needed-urgently Am J Respir Crit Care Med 182 2010 863 864
10. L.M. Fabbri, F. Luppi, B. Beghe, and K.F. Rabe Complex chronic comorbidities of COPD Eur Respir J 31 2008 204 212
11. M.K. Han, A. Agusti, and P.M. Calverley COPD Phenotypes: the future of COPD Am J Respir Crit Care Med 182 2010 598 604
12. A. Agusti, P. Sobradillo, and B. Celli Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine Am J Respir Crit Care Med 183 2011 1129 1137
13. A.M. Schols, J. Slangen, L. Volovics, and E.F. Wouters Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease Am J Respir Crit Care Med 157 1998 1791 1797
14. A.L. Ries, R.M. Kaplan, T.M. Limberg, and L.M. Prewitt Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease Ann Intern Med 122 1995 823 832
15. J.R. Hurst, J. Vestbo, and A. Anzueto Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med 363 2010 1128 1138
16. P.M.A. Calverley, J.A. Anderson, and B. Celli Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
17. D.P. Tashkin, B. Celli, and S. Senn A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
18. S.I. Rennard, D.P. Tashkin, and J. McElhattan Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial Drugs 69 2009 549 565
19. J.C. Hogg Pathophysiology of airflow limitation in chronic obstructive pulmonary disease Lancet 364 2004 709 721
20. F.J. Martinez, J.L. Curtis, and F. Sciurba Sex differences in severe pulmonary emphysema Am J Respir Crit Care Med 176 2007 243 252
21. J.V. Gosselink, S. Hayashi, and W.M. Elliott Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease Am J Respir Crit Care Med 181 2010 1329 1335
22. A. Fishman, F. Martinez, and K. Naunheim A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema N Engl J Med 348 2003 2059 2073
23. H.O. Coxson, J. Mayo, S. Lam, G. Santyr, G. Parraga, and D.D. Sin New and current clinical imaging techniques to study chronic obstructive pulmonary disease Am J Respir Crit Care Med 180 2009 588 597
24. A. Anzueto Impact of exacerbations on COPD Eur Respir Rev 19 2010 113 118
25. G.C. Donaldson, and J.A. Wedzicha COPD exacerbations. 1: Epidemiology Thorax 61 2006 164 168
26. J.A. Wedzicha, P.M. Calverley, T.A. Seemungal, G. Hagan, Z. Ansari, and R.A. Stockley The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am J Respir Crit Care Med 177 2008 19 26
27. T.M.A. Wilkinson, G.C. Donaldson, J.R. Hurst, T.A.R. Seemungal, and J.A. Wedzicha Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease Am J Respir Crit Care Med 169 2004 1298 1303
28. R. Kalhan, A. Arynchyn, L.A. Colangelo, M.T. Dransfield, L.B. Gerald, and L.J. Smith Lung function in young adults predicts airflow obstruction 20 years later Am J Med 123 2010 468 e1-7
29. R.S. Zeiger, C. Dawson, and S. Weiss Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP) J Allergy Clin Immunol 103 1999 376 387
30. R.J. Hancox, R. Poulton, and J.M. Greene Systemic inflammation and lung function in young adults Thorax 62 2007 1064 1068
31. D. Aronson, I. Roterman, and M. Yigla Inverse association between pulmonary function and C-reactive protein in apparently healthy subjects Am J Respir Crit Care Med 174 2006 626 632
32. D.M. Mannino, E.S. Ford, and S.C. Redd Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination Am J Med 114 2003 758 762
33. Y.M.T.A. van Durme, K.M.C. Verhamme, and A.-J.L.H.J. Aarnoudse C-reactive protein levels, haplotypes, and the risk of incident chronic obstructive pulmonary disease Am J Respir Crit Care Med 179 2009 375 382
34. G. Engstrom, N. Segelstorm, M. Ekberg-Aronsson, P.M. Nilsson, F. Lindgarde, and C.G. Lofdahl Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study Thorax 64 2009 211 215
35. R. Kalhan, B.T. Tran, and L.A. Colangelo Systemic inflammation in young adults is associated with abnormal lung function in middle age PLoS ONE 5 2010 e11431
36. W.Q. Gan, S.F. Man, and D.D. Sin The interactions between cigarette smoking and reduced lung function on systemic inflammation Chest 127 2005 558 564
37. R.E. Walter, J.B. Wilk, and M.G. Larson Systemic Inflammation and COPD: The Framingham Heart Study Chest 133 2008 19 25
38. D.D. Sin, and S.F. Man Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease Circulation 107 2003 1514 1519
39. M. Dahl, A. Tybjaerg-Hansen, J. Vestbo, P. Lange, and B.G. Nordestgaard Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 1008 1011
40. G. Engstrom, P. Lind, and B. Hedblad Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins Circulation 106 2002 2555 2560
41. B. Tran, and R. Kalhan The emerging role of systemic inflammation in chronic obstructive pulmonary disease Clin Pulm Med 15 2008 55 62
42. A.S. Cowburn, A.M. Condliffe, N. Farahi, C. Summers, and E.R. Chilvers Advances in neutrophil biology: clinical implications Chest 134 2008 606 612
43. D.E. O'Donnell, N. Voduc, M. Fitzpatrick, and K.A. Webb Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease Eur Respir J 24 2004 86 94
44. D.W. Perng, H.Y. Huang, H.M. Chen, Y.C. Lee, and R.P. Perng Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment Chest 126 2004 375 381
45. B.W. Willemse, N.H. ten Hacken, B. Rutgers, I.G. Lesman-Leegte, D.S. Postma, and W. Timens Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers Eur Respir J 26 2005 835 845
46. N.C. Barnes, Y.S. Qiu, and I.D. Pavord Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease Am J Respir Crit Care Med 173 2006 736 743
47. T.S. Lapperre, J.B. Snoeck-Stroband, and M.M. Gosman Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial Ann Intern Med 151 2009 517 527
48. Z.Y. He, L.M. Ou, and J.Q. Zhang Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease Respiration 80 2010 445 452
49. T.A. Seemungal, T.M. Wilkinson, J.R. Hurst, W.R. Perera, R.J. Sapsford, and J.A. Wedzicha Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations Am J Respir Crit Care Med 178 2008 1139 1147
50. P.A. Ford, A.L. Durham, R.E. Russell, F. Gordon, I.M. Adcock, and P.J. Barnes Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD Chest 137 2010 1338 1344
51. M. Kanehara, A. Yokoyama, and Y. Tomoda Anti-inflammatory effects and clinical efficacy of theophylline and tulobuterol in mild-to-moderate chronic obstructive pulmonary disease Pulm Pharmacol Ther 21 2008 874 878
52. D.C. Grootendorst, S.A. Gauw, and R.M. Verhoosel Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD Thorax 62 2007 1081 1087
53. D.D. Sin, B.E. Miller, and A. Duvoix Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease Am J Respir Crit Care Med 183 2011 1187 1192
54. F. Broeckaert, and A. Bernard Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker Clin Exp Allergy 30 2000 469 475
55. J.S. Lakind, S.T. Holgate, and D.R. Ownby A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects Biomarkers 12 2007 445 467
56. N.E. Alexis, J.C. Lay, and A. Haczku Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers Environ Health Perspect 116 2008 799 805
57. J. Vestbo, L.D. Edwards, and P.D. Scanlon Changes in forced expiratory volume in 1 second over time in COPD N Engl J Med 365 2011 1184 1192
58. S. Ma, Y.Y. Lin, L. Tartell, and G.M. Turino The effect of tiotropium therapy on markers of elastin degradation in COPD Respir Res 10 2009 12
59. C.A. Lindberg, G. Engstrom, and M. Gerhardsson de Verdier Total desmosines in plasma and urine correlate with lung function Eur Respir J 2011 [In press]
60. J.K. Stoller, F. Rouhani, and M. Brantly Biochemical efficacy and safety of a new pooled human plasma α(1)-antitrypsin Respitin. Chest 122 2002 66 74
61. V. Pinto-Plata, J. Toso, and K. Lee Profiling serum biomarkers in patients with COPD: associations with clinical parameters Thorax 62 2007 595 601
62. J.A. Wedzicha, T.A. Seemungal, and P.K. MacCallum Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels Thromb Haemost 84 2000 210 215
63. J.R. Hurst, W.R. Perera, T.M.A. Wilkinson, G.C. Donaldson, and J.A. Wedzicha Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease Am J Respir Crit Care Med 173 2006 71 78
64. J.R. Hurst, G.C. Donaldson, and W.R. Perera Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease Am J Respir Crit Care Med 174 2006 867 874
65. W.R. Perera, J.R. Hurst, and T.M. Wilkinson Inflammatory changes, recovery and recurrence at COPD exacerbation Eur Respir J 29 2007 527 534
66. T. Seemungal, R. Harper-Owen, and A. Bhowmik Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 1618 1623
67. K.H. Groenewegen, D.S. Postma, W.C. Hop, P.L. Wielders, N.J. Schlosser, and E.F. Wouters Increased systemic inflammation is a risk factor for COPD exacerbations Chest 133 2008 350 357
68. D. Dev, E. Wallace, and R. Sankaran Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease Respir Med 92 1998 664 667
69. M.A. Dentener, E.C. Creutzberg, and A.M. Schols Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations Thorax 56 2001 721 726
70. G.C. Donaldson, T. Seemungal, A. Bhowmik, and J.A. Wedzicha Relationship between exacerbation frequencly and lung function decline in chronic obstructive pulmonary disease Thorax 57 2002 847 852
71. T.A. Seemungal, G.C. Donaldson, E.A. Paul, J.C. Bestall, D.J. Jeffries, and J.A. Wedzicha Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 157 1998 1418 1422
72. J.J. Soler-Cataluna, M.A. Martinez-Garcia, P. Roman Sanchez, E. Salcedo, M. Navarro, and R. Ochando Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax 60 2005 925 931
73. G.C. Donaldson, T.A.R. Seemungal, and I.S. Patel Airway and systemic inflammation and decline in lung function in patients with COPD Chest 128 2005 1995 2004
74. S. Bozinovski, A. Hutchinson, and M. Thompson Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease Am J Respir Crit Care Med 177 2008 269 278
75. D. Stolz, M. Christ-Crain, and N.G. Morgenthaler Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD Chest 131 2007 1058 1067
76. D.A. Lomas, E.K. Silverman, L.D. Edwards, B.E. Miller, H.O. Coxson, and R. Tal-Singer Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort Thorax 63 2008 1058 1063
77. D.A. Lomas, E.K. Silverman, and L.D. Edwards Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD Eur Respir J 34 2009 95 102
78. B.R. Celli, C.G. Cote, and J.M. Marin The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease N Engl J Med 350 2004 1005 1012
79. K.-C. Ong, A. Earnest, and S.-J. Lu A Multidimensional grading system (BODE index) as predictor of hospitalization for COPD Chest 128 2005 3810 3816
80. S. Imfeld, K.E. Bloch, W. Weder, and E.W. Russi The BODE index after lung volume reduction surgery correlates with survival Chest 129 2006 873 878
81. C.G. Cote, and B.R. Celli Pulmonary rehabilitation and the BODE index in COPD Eur Respir J 26 2005 630 636
82. E. Pompeo, and T.C. Mineo Two-year improvement in multidimensional body mass index, airflow obstruction, dyspnea, and exercise capacity index after nonresectional lung volume reduction surgery in awake patients Ann Thorac Surg 84 2007 1862 1869 discussion 9
83. M.A. Puhan, J. Garcia-Aymerich, and M. Frey Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index Lancet 374 2009 704 711
84. R.C. Jones, G.C. Donaldson, and N.H. Chavannes Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE index Am J Respir Crit Care Med 180 2009 1189 1195
85. S.F. Liu, C.H. Chin, C.C. Wang, and M.C. Lin Correlation between serum biomarkers and BODE index in patients with stable COPD Respirology (Carlton, Vic) 14 2009 999 1004
86. M.K. Han, B. Bartholmai, and L.X. Liu Clinical significance of radiologic characterizations in COPD COPD 6 2009 459 467
87. T.B. Grydeland, A. Dirksen, and H.O. Coxson Quantitative computed tomography measures of emphysema and airway wall thickness are related to respiratory symptoms Am J Respir Crit Care Med 181 2010 353 359
88. A.A. Diaz, C. Valim, and T. Yamashiro Airway count and emphysema assessed by chest CT imaging predicts clinical outcome in smokers Chest 138 2010 880 887
89. A.A. Diaz, C.E. Come, and J.C. Ross Association between airway caliber changes with lung inflation and emphysema assessed by volumetric CT in subjects with COPD Chest 2011 [In press]
90. M.K. Han, R. Wise, and J. Mumford Prevalence and clinical correlates of bronchoreversibility in severe emphysema Eur Respir J 35 2010 1048 1056
91. J. Bignon, F. Khoury, P. Even, J. Andre, and G. Brouet Morphometric study in chronic obstructive bronchopulmonary disease. Pathologic, clinical, and physiologic correlations The American review of respiratory disease 99 1969 669 695
92. K. Matsuba, and W.M. Thurlbeck The number and dimensions of small airways in emphysematous lungs Am J Pathol 67 1972 265 275
93. J.E. McDonough, R. Yuan, and M. Suzuki Small-airway obstruction and emphysema in chronic obstructive pulmonary disease N Engl J Med 365 2011 1567 1575
94. Y. Nakano, S. Muro, and H. Sakai Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function Am J Respir Crit Care Med 162 2000 1102 1108
95. T. Ohara, T. Hirai, and S. Muro Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD Chest 134 2008 1244 1249
96. J. Bon, C.R. Fuhrman, and J.L. Weissfeld Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort Am J Respir Crit Care Med 183 2011 885 890
97. P. Boschetto, M. Miniati, and D. Miotto Predominant emphysema phenotype in chronic obstructive pulmonary Eur Respir J 21 2003 450 454
98. V.V. Damiano, A. Tsang, and U. Kucich Immunolocalization of elastase in human emphysematous lungs J Clin Invest 78 1986 482 493
99. A. Haruna, S. Muro, and Y. Nakano CT scan findings of emphysema predict mortality in COPD Chest 138 2010 635 640
100. P.A. Dawkins, L.J. Dowson, P.J. Guest, and R.A. Stockley Predictors of mortality in α1-antitrypsin deficiency Thorax 58 2003 1020 1026
101. F.J. Martinez, G. Foster, and J.L. Curtis Predictors of mortality in patients with emphysema and severe airflow obstruction Am J Respir Crit Care Med 173 2006 1326 1334
102. J.M. Bon, J.K. Leader, and J.L. Weissfeld The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease PLoS ONE 4 2009 e6865
103. S. Matsuoka, T. Yamashiro, and A. Diaz The relationship between small pulmonary vascular alteration and aortic atherosclerosis in chronic obstructive pulmonary disease: quantitative CT analysis Acad Radiol 18 2011 40 46
104. R.G. Barr, D.A. Bluemke, and F.S. Ahmed Percent emphysema, airflow obstruction, and impaired left ventricular filling N Engl J Med 362 2010 217 227